seasonal

Missed the dip? Why November’s wobble could still set up your next decade

Ruben Dalfovo
Ruben Dalfovo

Investment Strategist

Key takeaways

  • Seasonal patterns in November and December are real but small, better for managing expectations than timing the perfect low.
  • Recent weakness in Nvidia and strength in healthcare hint at a broader market that no longer relies on one hero stock.
  • Retail investors who missed the dip can still phase in, diversify, and focus on seasons, not single stormy days.


You can almost picture the scene. It is early November, markets look tired, headlines talk about corrections and bubbles, and many investors decide to “wait for a proper dip”.

Then volatility hits, indexes lurch lower for a few days, healthcare and other defensives perk up, and artificial intelligence favourites wobble. Before most people have finished debating what to do, prices rebound. By late November, a familiar feeling returns: “I waited, markets bounced, and I missed it again.”

This is where seasonality can help, not as a trading signal, but as a way to reframe the whole problem. Markets really do have “seasons” around year end, yet those patterns are far too small and noisy to pick the perfect day. Used properly, they are a reminder to think in years, not weeks, and to spread entries across a broader market that is no longer just Nvidia plus friends.

Market seasons are gentle nudges, not marching orders

Let us start with what the calendar actually tells us. Historically, the final stretch of the year has been a slightly kinder period for equities. The so called “Santa Claus rally” describes a tendency for stocks to rise in the last five trading days of December and the first two of January, with the S&P 500 averaging around a 1.3% gain in that seven-day window and posting positive returns in roughly three out of four years.

Zoom out, and November and December have often ranked among the stronger months for US stocks, but only by a few percentage points and with plenty of exceptions. Some years deliver strong rallies, others drift sideways, and there are still painful end of year selloffs. Seasonality is more like a gentle tailwind than a guarantee.

The more important statistic is how time works with you as the horizon stretches. Over nearly a century of data, the S&P 500 has been positive in only about 59% of individual months, which barely beats a coin toss. Yet every 20-year holding period has delivered a positive total return. In other words, the odds tilt in your favour because of time in the market, not because November is slightly better than June.

So if you feel you “missed” the brief weakness earlier this month, seasonality offers two practical lessons. First, short term wobbles are normal and often resolve quickly, which is exactly what made timing so hard in the first place. Second, there will be many more Novembers and Decembers. The key is to build a plan for all of them, instead of treating this one as a once in a lifetime entry point.

time_in_the_market_vs_timing_the_dip_RIGHT

From one hero stock to a broader cast

For most of the artificial intelligence story, Nvidia has felt like the main character. Since the launch of ChatGPT in November 2022, its shares have climbed roughly tenfold, turning the company into a symbol of the entire AI build out. That is also why recent wobbles have captured so much attention.

In the past few weeks, concerns about competition from Alphabet’s tensor processing units and potential chip deals with big cloud customers have weighed on Nvidia. At the same time, Alphabet and Broadcom have been stronger, helped by excitement around new AI models and infrastructure demand. The message from the tape is not “AI is over”. It is that leadership within the theme is rotating, and the market is learning to reward other parts of the stack, such as cloud platforms and networking.

Beyond AI, healthcare has quietly stolen the show. Recent data suggest the S&P 500 Health Care Index has gained around mid-single digits in November, while the wider market has slipped and technology has been the weakest sector. Fund managers have increased their healthcare allocations, attracted by steady earnings, obesity drug growth and the defensive appeal of the sector after a long period in tech’s shadow.

For investors sitting on cash, this is actually good news. A market that rewards more than one story is easier to enter. Instead of feeling forced to buy the latest AI favourite at any price, you can build a mix of broad indices, healthcare exposure and selected themes that reflect different parts of the economy. The rotation into healthcare, and the broader leadership beyond Nvidia, effectively doubles as a second chance for those who missed the first AI wave.

Risks: when seasons and rotations both mislead

None of this means the path from here is smooth. Seasonality can fail outright in the face of a major shock, whether from geopolitics, central banks or a sudden earnings downturn. A year end that “should” be positive can still deliver a sharp correction, as 2018 and other episodes have shown.

There is also a risk that investors overread the latest sector rotation. Healthcare’s outperformance in November partly reflects worries about an AI bubble and stretched tech valuations. If those fears ease, leadership could swing back quickly, leaving anyone who piled into “what has just worked” feeling whipsawed yet again.

Finally, a broader market is not a cheaper market. Parts of healthcare and AI infrastructure already trade on rich expectations. Even if these sectors remain stronger than average, returns from today’s prices could be bumpier than recent headlines suggest.

From missed dips to better plans

The temptation after a fast rebound is to focus on the missed moment. You remember the afternoon you nearly clicked “buy” and the headline that scared you away. From that angle, November’s brief wobble feels like one more chapter in a long story of bad timing.

Seasonality offers a kinder lens. Historically, late year markets are slightly more favourable, but only by enough to reward those who are already participating, not those waiting for a postcard perfect entry. At the same time, the recent rotation away from a single hero stock toward healthcare and other sectors shows that the opportunity set is wider than it looked a few months ago.

For long-term investors, the useful response is not to chase the latest winner, nor to obsess over the low that got away. It is to accept that there will always be another November, another wobble and another surprise leader, and to build a plan that can live through all of them without needing to guess which week to move.


This material is marketing content and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results.

The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.

Quarterly Outlook

01 /

  • Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu

    Quarterly Outlook

    Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q4 Outlook for Traders: The Fed is back in easing mode. Is this time different?

    Quarterly Outlook

    Q4 Outlook for Traders: The Fed is back in easing mode. Is this time different?

    John J. Hardy

    Global Head of Macro Strategy

    The Fed launched a new easing cycle in late Q3. Will this cycle now play out like 2000 or 2007?
  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.


Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.